Entrada Therapeutics (NASDAQ:TRDA) COO Sells $155,216.70 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) COO Nathan Dowden sold 11,894 shares of Entrada Therapeutics stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $13.05, for a total value of $155,216.70. Following the transaction, the chief operating officer owned 198,588 shares in the company, valued at $2,591,573.40. This trade represents a 5.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Entrada Therapeutics Stock Performance

NASDAQ TRDA traded up $0.30 during trading hours on Wednesday, reaching $13.50. 210,880 shares of the company’s stock were exchanged, compared to its average volume of 236,376. The company’s 50-day moving average is $11.16 and its two-hundred day moving average is $8.83. Entrada Therapeutics, Inc. has a one year low of $4.93 and a one year high of $13.66. The company has a market capitalization of $516.78 million, a price-to-earnings ratio of -3.90 and a beta of -0.12.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.94) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.38. The firm had revenue of $1.30 million for the quarter, compared to analyst estimates of $7.41 million. Entrada Therapeutics had a negative net margin of 565.48% and a negative return on equity of 39.83%. Research analysts predict that Entrada Therapeutics, Inc. will post 1.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Royce & Associates LP lifted its position in Entrada Therapeutics by 54.8% during the 3rd quarter. Royce & Associates LP now owns 345,507 shares of the company’s stock worth $2,004,000 after buying an additional 122,256 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in Entrada Therapeutics in the second quarter valued at approximately $166,000. Los Angeles Capital Management LLC increased its position in shares of Entrada Therapeutics by 60.6% during the 2nd quarter. Los Angeles Capital Management LLC now owns 44,632 shares of the company’s stock worth $300,000 after purchasing an additional 16,840 shares during the last quarter. GSA Capital Partners LLP acquired a new position in shares of Entrada Therapeutics during the 3rd quarter worth approximately $325,000. Finally, Russell Investments Group Ltd. raised its stake in shares of Entrada Therapeutics by 72.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company’s stock worth $51,000 after purchasing an additional 3,707 shares in the last quarter. Institutional investors own 86.39% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Entrada Therapeutics in a research note on Monday, December 29th. Guggenheim raised Entrada Therapeutics to a “strong-buy” rating in a research note on Wednesday, February 11th. Oppenheimer began coverage on Entrada Therapeutics in a report on Wednesday, January 28th. They issued an “outperform” rating and a $21.00 price target on the stock. Wall Street Zen raised Entrada Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Entrada Therapeutics in a research report on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $18.50.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.